Early test results of interferon slugs were published in the Lancet sub-issue

So far, there are not many drugs that effectively treat new coronavirus diseases (COVID-19).
The Lancet-Respiratory Medicine recently published the results of a Phase 2 clinical trial from the Canadian team: The treatment of the antiviral drug Peginterferon lambda significantly accelerated the recovery of COVID-19 outpatients, who were four times more likely to be cleared of viral infection within 7 days than in placebo therapy.
potential therapy may help curb the spread of communities because in many countries, patients with mild illness do not need hospitalization.
interferon is a protein involved in congenesome antiviral reactions that is active against respiratory pathogens.
new coronavirus can prevent the body from producing interferons, which activate a variety of cellular pathways that kill the virus.
Unlike other interferons, interferon-tyrennogen's subjects are found only in certain tissues in the body and are common in areas where new coronavirus such as the lungs, liver, and intestines can replicate, while in others they are less active, meaning that their potential side effects are smaller.
the placebo-controlled double-blind randomized clinical trial, a total of 60 nucleic acid-positive outpatient subjects received subsuplic injections of interferon pyrethrin (180 μg) or a placebo at 1:1.
treatment within 7 days of onset or when the first swab is positive (e.g. asymptomatic).
from day 3, the decrease in viral load was more pronounced in patients in the interferon group, with a difference of 2.42 log copy/mL from the placebo group on day 7.
on the 7th day, 24 cases (80%) of the participants in the interferon group had untestable viral loads, while the placebo group had 19 (63%) (p s 0.15).
after adjusting the baseline viral load, patients in the interferon group were 4.12 times more likely to detect the virus on the 7th day (p s 0.029).
in patients with higher baseline viral loads (>106 copies/ml), patients in the interferon group were 6.25 times more likely to detect the virus on the 7th day (79% (15/19 cases) than those in the placebo group. The vs 38% (6 cases/16 cases, p -0.012) study also observed a trend of interferon radon accelerating the improvement of respiratory symptoms, with 1 case in the interferon group and 4 patients in the placebo group requiring emergency medical attention due to worsening respiratory symptoms.
resistance to polyethyl glycol interferon, mild and transaminase elevation adverse events were similar between the two groups.
two groups of patients with elevated transaminase to level 3 adverse events, and no other level 3 or 4 adverse events were reported.
team noted that speeding up virus removal can reduce the risk of severe illness and the risk of patients spreading the disease to others.
these positive results, the research team plans to launch a large Phase 3 trial in the near future.
teams from the University of Toronto, Harvard University and Johns Hopkins University are also conducting other studies, including the use of polyethyl glycol interferon in inpatients and exposure prevention.
: . . . Jordan J. Feld, et al., (2021). Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respiratory Medicine, DOI: 10.1016/S2213-2600(20)30566-X[2] Peginterferon-lambda shows strong antiviral action to accelerate clearance of COVID-19. Retrieved February 7, 2021, from